September 16, 2024

Supplemental Figure 6 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Supplemental Figure 6. Cell survival of GIST T1 cells treated with imatinib or avapritinib for 72h in complete media. Each data point represents an average of 10 wells.

Me gusta

Guardar

Cite This Study

Rossi et al. (Mon,) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522dce https://doi.org/https://doi.org/10.1158/1078-0432.27030505.v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 6 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor2024
2Supplemental Figure 2 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor2024
3Supplemental Figure 2 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor2024
4Supplemental Figure 8 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor2024
5Supplemental Figure 8 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor2024

Me gusta

Guardar